Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207940
Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Hereditary leiomyomatosis and renal cell cancer syndrome is a rare autosomal dominant hereditary syndrome. Previously, we published the largest cohort of FH mutation carriers in Spain and observed a highly recurrent missense heterozygous variant, FH(NM_000143.4):c.1118A > G p.(Asn373Ser), in 104 individuals from 31 apparently unrelated families. Here, we aimed to establish its founder effect and characterize the associated clinical phenotype. Results Haplotype analysis confirmed that families shared a common haplotype (32/38 markers) spanning 0.61-0.82 Mb, indicating this recurrent variant was inherited from a founder ancestor. Cutaneous and uterine leiomyomatosis were diagnosed in 64.6% (64/99) and 98% (50/51) of patients, respectively, and renal cell cancer was present in 10.4% (10/96). The pathogenic FH_c.1118A > G variant is a Spanish founder mutation that originated 12-26 generations ago. We estimate that the variant may have appeared between 1370 and 1720. Individuals carrying this founder mutation had similar frequency of renal cell cancer and a higher frequency of renal cysts and leiomyomas than those in other cohorts of this syndrome. Conclusions In the Spanish province of Alicante there is a high prevalence of HLRCC because of the founder mutation FH c.1118A > G; p.(Asn373Ser). The characterization of founder mutations provides accurate and specific information regarding their penetrance and expressivity. In individuals with suspected HLRCC from the province of Alicante, genetic testing by direct analysis of the founder FH c.1118A > G; p.(Asn373Ser) mutation may be a faster and more efficient diagnostic tool compared with complete gene sequencing.
Matèries (anglès)
Citació
Citació
SÁNCHEZ HERAS, Ana beatriz, DÁMASO, Estela, CASTILLEJO, Adela, ROBLEDO, Mercedes, TEULÉ, Alexandre, LÁZARO GARCÍA, Conxi, SÁNCHEZ MARTÍNEZ, Rosario, ZÚÑIGA, Ángel, LÓPEZ FERNÁNDEZ, Adrià, BALMAÑA, Judith, ROBLES, Luis, RAMON Y CAJAL, Teresa, CASTILLEJO, M. isabel, IBAÑEZ, Raquel perea, SEVILA, Carmen martínez, SÁNCHEZ MIRA, Andrea, ESCANDELL, Inés, GÓMEZ, Luís, BERBEL, Pere, SOTO, José luis. Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome. _Orphanet Journal of Rare Diseases_. 2024. Vol. 19, núm. 1. [consulta: 1 de febrer de 2026]. ISSN: 1750-1172. [Disponible a: https://hdl.handle.net/2445/207940]